KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) EBT (2020 - 2025)

Historic EBT for Ginkgo Bioworks Holdings (DNA) over the last 6 years, with Q3 2025 value amounting to -$80.8 million.

  • Ginkgo Bioworks Holdings' EBT fell 4222.76% to -$80.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$340.1 million, marking a year-over-year increase of 4780.6%. This contributed to the annual value of -$547.5 million for FY2024, which is 3868.48% up from last year.
  • Ginkgo Bioworks Holdings' EBT amounted to -$80.8 million in Q3 2025, which was down 4222.76% from -$60.6 million recorded in Q2 2025.
  • Ginkgo Bioworks Holdings' EBT's 5-year high stood at -$54.9 million during Q2 2021, with a 5-year trough of -$1.6 billion in Q4 2021.
  • For the 5-year period, Ginkgo Bioworks Holdings' EBT averaged around -$296.4 million, with its median value being -$173.2 million (2023).
  • In the last 5 years, Ginkgo Bioworks Holdings' EBT plummeted by 336118.43% in 2021 and then soared by 8830.1% in 2022.
  • Ginkgo Bioworks Holdings' EBT (Quarter) stood at -$1.6 billion in 2021, then surged by 88.3% to -$187.8 million in 2022, then fell by 12.8% to -$211.9 million in 2023, then skyrocketed by 49.1% to -$107.9 million in 2024, then rose by 25.13% to -$80.8 million in 2025.
  • Its EBT stands at -$80.8 million for Q3 2025, versus -$60.6 million for Q2 2025 and -$90.9 million for Q1 2025.